论文部分内容阅读
目的:评价前列腺癌根治性前列腺切除术前内分泌治疗的作用。方法:患者术前接受3个月(仅1例为6个月)的雄激素最大限度阻断治疗(LHRH类似物加非甾体抗雄激素药物)。结果:31例患者平均随访40.3个月(18～72个月)。治疗后PSA均下降,28例(90.3%)降至0.5ng/ml以下,3例(9.7%)未降至0.5ng/ml,其中2例术后PSA升高和局部复发。治疗后临床分期与治疗前相比降低4例(12.9%),升高5例(16.1%)。前列腺切缘肿瘤阳性2例(6.5%)。8例(25.8%)术后20.4个月(6～50个月)出现PSA升高,其中6例(19.4%)术后33.2个月(13～59个月)肿瘤复发,1例死亡。结论:经新辅助内分泌治疗,临床分期和前列腺切缘肿瘤的阳性率降低。
Objective: To evaluate the effect of endocrine therapy before radical prostatectomy of prostate cancer. METHODS: Patients received maximum androgen blockade (LHRH analogue plus NSAID) for 3 months (1 in 6 months) preoperatively. Results: The average follow-up of 31 patients was 40.3 months (18 to 72 months). After treatment, PSA decreased, 28 cases (90.3%) dropped below 0.5ng / ml, 3 cases (9.7%) did not reduce to 0.5ng / ml, including 2 cases of postoperative PSA increased and local recurrence. After treatment, the clinical stage was lower in 4 cases (12.9%) and in 5 cases (16.1%) than before treatment. Prostate incision tumors were positive in 2 cases (6.5%). Eight patients (25.8%) developed PSA elevation at 20.4 months (6 to 50 months) after surgery. Six patients (19.4%) developed tumor recurrence at 33.2 months (13 to 59 months) and one patient died after operation. Conclusion: The neoadjuvant endocrine therapy reduces the positive rate of clinical staging and prostate cancer.